Logo
x

Search

Subscribe Now

travere therapeutics

Travere Therapeutics’ Filspari (sparsentan) Receives the US FDA’s Full Approval for Treating IgA Nephropathy

Travere Therapeutics’ Filspari (sparsentan) Receives the US FDA’s Full Approval for Treating IgA Nephropathy

  • September 6, 2024
PharmaShots Weekly Snapshots (March 11 – March 15, 2024)

PharmaShots Weekly Snapshots (March 11 – March 15, 2024)

  • March 15, 2024
Travere Therapeutics Reports sNDA Submission of Filspari (sparsentan) to the US FDA for Treating IgA Nephropathy (IgAN)

Travere Therapeutics Reports sNDA Submission of Filspari (sparsentan) to the US FDA for Treating IgA Nephropathy (IgAN)

  • March 12, 2024
Travere Therapeutics Report Results for Filspari in 2 P-III Trial for the Treatment of IgA Nephropathy (IgAN) and Focal Segmental Glomerulosclerosis (FSGS)

Travere Therapeutics Report Results for Filspari in 2 P-III Trial for the Treatment of IgA Nephropathy (IgAN) and Focal Segmental...

  • November 7, 2023
Travere Therapeutics’ Filspari (sparsentan) Receives the US FDA’s Approval for the Reduction of Proteinuria in IgA Nephropathy

Travere Therapeutics’ Filspari (sparsentan) Receives the US FDA’s Approval for the Reduction of Proteinuria in IgA Nephropathy

  • February 21, 2023
Travere Therapeutics Reports US FDA Acceptance of NDA and Priority Review for Sparsentan to Treat IgA Nephropathy

Travere Therapeutics Reports US FDA Acceptance of NDA and Priority Review for Sparsentan to Treat IgA Nephropathy

  • May 17, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.